BIO President and CEO Jim Greenwood made statement regarding California State Assembly's burdensome legislation. "While the Assembly’s efforts to address health care costs for patients are well intended, the Pharmaceutical Cost Transparency Act of 2015 (AB 463) does nothing to improve patient access to medicines that have been put virtually out of reach by insurance company specialty tiers that have such high copays and co-insurance requirements that patients feel they no longer have insurance."